Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s AKP Takes Over Artisan To Progress ART-123

This article was originally published in PharmAsia News

Executive Summary

Japan's Asahi Kasei Pharma announced Nov. 22 that its acquisition of Massachusetts-based Artisan Pharma, a company it spun out in 2006.

You may also be interested in...

The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb

Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.

Artisan, Singapore's A-Bio Join Forces On Recombinant Sepsis Candidate

Artisan Pharma and Singapore-based A-Bio Pharma have established a relationship under which the Asian firm will provide process development, scale-up and manufacturing support for Artisan's investigational recombinant protein ART-123, the firms announced Sept. 17

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts